Preprint Article Version 1 This version is not peer-reviewed

Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent

Version 1 : Received: 12 July 2024 / Approved: 15 July 2024 / Online: 15 July 2024 (13:41:31 CEST)

How to cite: Vatté, J.; Bourdeau, V.; Ferbeyre, G.; Schmitzer, A. Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent. Preprints 2024, 2024071193. https://doi.org/10.20944/preprints202407.1193.v1 Vatté, J.; Bourdeau, V.; Ferbeyre, G.; Schmitzer, A. Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent. Preprints 2024, 2024071193. https://doi.org/10.20944/preprints202407.1193.v1

Abstract

AUTAC-Biguanide is a hybrid compound designed to target mitochondria inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide's superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to triggers mitophagy. By providing a comprehensive analysis of these findings, the study adds valuable insights to the field of mitochondrial-targeting anticancer agents.

Keywords

AUTAC; biguanide; pancreatic cancer

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.